(Q37902639)

25 August 2017

1 reference

title

Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma (English)

1 reference

25 August 2017

1 reference

1 reference

Nagendra Natarajan

1

1 reference

25 August 2017

Sucheta Telang

series ordinal

2

1 reference

25 August 2017

Donald Miller

series ordinal

3

1 reference

25 August 2017

Jason Chesney

series ordinal

4

1 reference

25 August 2017

publication date

1 July 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

71

1 reference

25 August 2017

issue

10

1 reference

25 August 2017

page(s)

1233-1250

1 reference

https://scigraph.springernature.com/pub.10.2165/11591380-000000000-00000

25 August 2017

exact match

0 references

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Management of melanoma: a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Human T cell responses against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

MHC class I antigens and immune surveillance in transformed cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Interleukin-2: inception, impact, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

PD-1 and PD-1 ligands: from discovery to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Phase 2 trial of Allovectin-7 in advanced metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Successful treatment of melanoma brain metastases with adoptive cell therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

CD25+ regulatory T cells and tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Transient T cell depletion causes regression of melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Mutant BRAF melanomas--dependence and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Resistance to BRAF inhibition in melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Analysis of the genome to personalize therapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Phase II trial of imatinib mesylate in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Lack of clinical efficacy of imatinib in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Melanoma from bench to bedside: meeting report from the 6th international melanoma congress.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591380-000000000-00000

A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3.

21 January 2018

1 reference

12 December 2020

IL-21 Counteracts the Regulatory T Cell-Mediated Suppression of Human CD4+ T Lymphocytes

1 reference

12 December 2020

1 reference

12 December 2020

A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling

1 reference

12 December 2020

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

12 December 2020

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

1 reference

12 December 2020

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

1 reference

12 December 2020

Immunotherapy with agonistic anti-CD137: two sides of a coin.

1 reference

12 December 2020

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.

1 reference

12 December 2020

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

12 December 2020

Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses

1 reference

12 December 2020

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma

1 reference

12 December 2020

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

12 December 2020

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

12 December 2020

Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice

1 reference

12 December 2020

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy

1 reference

12 December 2020

Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis

1 reference

12 December 2020

Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking

1 reference

12 December 2020

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

12 December 2020

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

12 December 2020

A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18

1 reference

12 December 2020

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

1 reference

12 December 2020

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

1 reference

12 December 2020

10.2165/11591380-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1013726931

0 references

1 reference